Gilead Sciences (GILD) 105.47 $GILD
Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...
Final Glance: Biotechnology companies
AP - Mon Sep 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Glaxo Fined Roughly $484M in China Bribery Probe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:45PM CDT
GlaxoSmithKline (GSK) announced that it has been found guilty of bribing non-government personnel by the Changsha Intermediate People's Court in Hunan Province, China.
Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.
Flexion Continues to Fall Post Clinical Hold on FX006 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:59PM CDT
Flexion announced that the FDA has placed a clinical hold on patient enrollment and dosing in an ongoing phase IIb study on FX006.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Midday Glance: Biotechnology companies
AP - Mon Sep 22, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Gilead Sciences (GILD) Crosses Pivot Point Support at $105.02
Comtex SmarTrend(R) - Mon Sep 22, 12:27PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $106.45 today and has reached the first level of support at $105.02. Investors may be interested in a cross of the next downside pivot targets of $104.07 and $101.69.
Gilead Sciences: A Preview of Important HIV Drug Study Results
at The Street - Mon Sep 22, 11:44AM CDT
Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.
Early Glance: Biotechnology companies
AP - Mon Sep 22, 10:05AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo
PR Newswire - Mon Sep 22, 8:05AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6643-100free.
Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:51AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as its shares rose almost 7% on the day.
Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...
Final Glance: Biotechnology companies
AP - Mon Sep 22, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Glaxo Fined Roughly $484M in China Bribery Probe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:45PM CDT
GlaxoSmithKline (GSK) announced that it has been found guilty of bribing non-government personnel by the Changsha Intermediate People's Court in Hunan Province, China.
Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.
Flexion Continues to Fall Post Clinical Hold on FX006 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:59PM CDT
Flexion announced that the FDA has placed a clinical hold on patient enrollment and dosing in an ongoing phase IIb study on FX006.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Midday Glance: Biotechnology companies
AP - Mon Sep 22, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Gilead Sciences (GILD) Crosses Pivot Point Support at $105.02
Comtex SmarTrend(R) - Mon Sep 22, 12:27PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $106.45 today and has reached the first level of support at $105.02. Investors may be interested in a cross of the next downside pivot targets of $104.07 and $101.69.
Gilead Sciences: A Preview of Important HIV Drug Study Results
at The Street - Mon Sep 22, 11:44AM CDT
Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.
Early Glance: Biotechnology companies
AP - Mon Sep 22, 10:05AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:39AM CDT
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as its shares rose over 6% on the day.
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo
PR Newswire - Mon Sep 22, 8:05AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6643-100free.
Vertex Pharmaceuticals (VRTX) Jumps: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:51AM CDT
Vertex Pharmaceuticals Incorporated (VRTX) was a big mover last session, as its shares rose almost 7% on the day.
Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:25PM CDT
VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals, Inc. (AUXL) announced that the FDA has approved Stendra's supplemental new drug application.
Most active Nasdaq-traded stocks
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
